CD38 and neoplasm: Gene-editing technologies (e.g., CRISPR/Cas9) have markedly augmented CAR-NK cell function, for instance, through knockout of inhibitory receptors (e.g., CISH, TGF-βR2) or metabolism-related genes (e.g., CD38), thereby improving both anti-tumor activity and adaptability to the TME.